2023
Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria
Ivanics T, Claasen M, Samstein B, Emond J, Fox A, Pomfret E, Pomposelli J, Tabrizian P, Florman S, Mehta N, Roberts J, Emamaullee J, Genyk Y, Hernandez-Alejandro R, Tomiyama K, Sasaki K, Hashimoto K, Nagai S, Abouljoud M, Olthoff K, Hoteit M, Heimbach J, Taner T, Liapakis A, Mulligan D, Sapisochin G, Halazun K, Group O. Living Donor Liver Transplantation for Hepatocellular Carcinoma Within and Outside Traditional Selection Criteria. Annals Of Surgery 2023, 279: 104-111. PMID: 37522174, DOI: 10.1097/sla.0000000000006049.Peer-Reviewed Original ResearchConceptsUniversity of California San FranciscoMilan criteriaDonor liver transplantationHepatocellular carcinomaOverall survivalLiver transplantationPosttransplantation survivalEvaluate long-term oncologic outcomesUniversity of California San Francisco criteriaLiving donor liver transplantationRecurrence-free survivalKaplan-Meier methodTransplant selection criteriaProportion of patientsAdult LDLT recipientsNorth American centersLong-term survivalLiver transplant waitlistCalifornia San FranciscoLDLT recipientsMulticenter cohortConsensus guidelinesTransplantationPatientsPosttransplantationPredicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning
Kucukkaya A, Zeevi T, Chai N, Raju R, Haider S, Elbanan M, Petukhova-Greenstein A, Lin M, Onofrey J, Nowak M, Cooper K, Thomas E, Santana J, Gebauer B, Mulligan D, Staib L, Batra R, Chapiro J. Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning. Scientific Reports 2023, 13: 7579. PMID: 37165035, PMCID: PMC10172370, DOI: 10.1038/s41598-023-34439-7.Peer-Reviewed Original ResearchLiving donor liver transplant candidate and donor selection and engagement: Meeting report from the living donor liver transplant consensus conference
Jesse M, Jackson W, Liapakis A, Ganesh S, Humar A, Goldaracena N, Levitsky J, Mulligan D, Pomfret E, Ladner D, Roberts J, Mavis A, Thiessen C, Trotter J, Winder G, Griesemer A, Pillai A, Kumar V, Verna E, Rudow D, Han H, Group T. Living donor liver transplant candidate and donor selection and engagement: Meeting report from the living donor liver transplant consensus conference. Clinical Transplantation 2023, 37: e14954. PMID: 36892182, DOI: 10.1111/ctr.14954.Peer-Reviewed Original ResearchConceptsDonor selectionConsensus conferenceDeceased donor organ shortageDonor liver transplantationLiver transplant candidatesDonor organ shortageLiver transplantationTransplant candidatesWaitlist mortalityExcellent outcomesLDLT candidatesOrgan shortageDonation outcomesLack of standardizationAmerican SocietyTransplantationDelphi approachBroad implementationMeeting reportOutcomesCandidate indicationsReportLDLTPatientsBroad uptakeHonoring the gift: The transformative potential of transplant-declined human organs
Albert C, Harris M, DiRito J, Shi A, Edwards C, Harkins L, Lysyy T, Kulkarni S, Mulligan D, Hosgood S, Watson C, Friend P, Nicholson M, Haakinson D, Saeb-Parsy K, Tietjen G. Honoring the gift: The transformative potential of transplant-declined human organs. American Journal Of Transplantation 2023, 23: 165-170. PMID: 36695696, DOI: 10.1016/j.ajt.2022.11.015.Peer-Reviewed Original Research
2022
Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients
Banach DB, Lopez‐Verdugo F, Sanchez‐Garcia J, Tran A, Gomez‐Llerena A, Munoz‐Abraham A, Bertacco A, Valentino PL, Yoo P, Dembry L, Mulligan DC, Ekong UD, Emre SH, Rodriguez‐Davalos M. Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients. Transplant Infectious Disease 2022, 24: e13941. PMID: 35989545, DOI: 10.1111/tid.13941.Peer-Reviewed Original ResearchConceptsSurgical site infectionLiver transplant recipientsLiver transplantationBiliary complicationsGraft recipientsTransplant recipientsSite infectionRisk factorsOutcomes of SSIPediatric liver transplant recipientsLong-term graftPediatric liver transplantationRetrospective descriptive analysisPrimary endpointHospital daysPatient agePediatric populationPatient survivalSignificant causeComplicationsPatientsRecipientsOutcomesInfectionIncidenceClinical and Ethical Framework for Liver Retransplantation Using Living Donor Grafts: A Western Perspective
Batra RK, Mulligan DC. Clinical and Ethical Framework for Liver Retransplantation Using Living Donor Grafts: A Western Perspective. Liver Transplantation 2022, 28: 760-762. PMID: 34931433, DOI: 10.1002/lt.26395.Peer-Reviewed Original Research
2021
Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant
Merola J, Gan G, Stewart D, Noreen S, Mulligan D, Batra R, Haakinson D, Deng Y, Kulkarni S. Inactive status is an independent predictor of liver transplant waitlist mortality and is associated with a transplant centers median meld at transplant. PLOS ONE 2021, 16: e0260000. PMID: 34793524, PMCID: PMC8601542, DOI: 10.1371/journal.pone.0260000.Peer-Reviewed Original ResearchConceptsDonor service areasWaitlist mortalityTransplant centersMedian MELDHigh mortalityStatus changesLiver transplant waitlist mortalityDeceased donor transplantsInactive statusTransplant probabilityInactive patientsMELD scoreDonor transplantsHazard ratioIndependent predictorsTransplant ratesCare coordinationMortalityPatientsTransplantLevel cohortsTertileSignificant differencesCohortMELDDeveloping simultaneous liver‐kidney transplant medical eligibility criteria while providing a safety net: A 2‐year review of the OPTN's allocation policy
Wilk AR, Booker SE, Stewart DE, Wiseman A, Gauntt K, Mulligan D, Formica RN. Developing simultaneous liver‐kidney transplant medical eligibility criteria while providing a safety net: A 2‐year review of the OPTN's allocation policy. American Journal Of Transplantation 2021, 21: 3593-3607. PMID: 34254434, DOI: 10.1111/ajt.16761.Peer-Reviewed Original ResearchConceptsMedical Eligibility CriteriaEligibility criteriaLiver transplantPatient/graft survivalWaitlist mortality rateDeceased donor kidneysLiver recipientsSLK candidatesSLK transplantsGraft survivalRenal impairmentPosttransplant outcomesDonor kidneysTransplant ratesTransplant volumeMortality rateTransplantKidneySignificant differencesRecipientsSubsequent increaseLiver dataCriteriaImpairmentSLKAmerican Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Fix OK, Blumberg EA, Chang K, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ, Group F. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology 2021, 74: 1049-1064. PMID: 33577086, PMCID: PMC8014184, DOI: 10.1002/hep.31751.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineCOVID-19 vaccineChronic liver diseaseLiver diseaseModerna mRNA COVID-19 vaccinesCoronavirus disease 2019 (COVID-19) infectionExpert panel consensus statementPrevious drug reactionsAdvanced liver diseaseLiver transplant recipientsAvailable COVID-19 vaccinesDisease 2019 infectionSevere hypersensitivity reactionsLocal site reactionsCare of patientsClinical trial participantsHealth care providersLT recipientsTransplant recipientsAdult patientsImmunosuppressed patientsSystemic reactionsHypersensitivity reactionsSite reactionsVaccine efficacyNorth American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension
Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy MJ, Verna EC, Abraldes JG, Allegretti AS, Bajaj JS, Biggins SW, Darcy MD, Farr MA, Farsad K, Garcia-Tsao G, Hall SA, Jadlowiec CC, Krowka MJ, Laberge J, Lee EW, Mulligan DC, Nadim MK, Northup PG, Salem R, Shatzel JJ, Shaw CJ, Simonetto DA, Susman J, Kolli KP, VanWagner LB, Consortium A. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clinical Gastroenterology And Hepatology 2021, 20: 1636-1662.e36. PMID: 34274511, PMCID: PMC8760361, DOI: 10.1016/j.cgh.2021.07.018.Peer-Reviewed Original ResearchConceptsPortal hypertensionTIPS creationInterventional radiologistsTransjugular intrahepatic portosystemic shuntTransjugular intrahepatic portosystemic shunt (TIPS) creationPrevention of complicationsIntrahepatic portosystemic shuntCrucial therapeutic optionPortosystemic Shunt CreationPractice-based recommendationsUse of TIPSTIPS indicationGastrointestinal bleedingHepatic hydrothoraxHepatic encephalopathySignificant morbidityPortosystemic shuntTherapeutic optionsTransplant surgeryConsensus statementTherapeutic decisionsHypertensionApproach groupTherapeutic approachesShunt creationChanges in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy
Mullan CW, Chouairi F, Sen S, Mori M, Clark KAA, Reinhardt SW, Miller PE, Fuery MA, Jacoby D, Maulion C, Anwer M, Geirsson A, Mulligan D, Formica R, Rogers JG, Desai NR, Ahmad T. Changes in Use of Left Ventricular Assist Devices as Bridge to Transplantation With New Heart Allocation Policy. JACC Heart Failure 2021, 9: 420-429. PMID: 33714748, DOI: 10.1016/j.jchf.2021.01.010.Peer-Reviewed Original ResearchConceptsDonor heart allocation systemNumber of patientsHeart allocation systemVentricular assist deviceWaitlist survivalAssist deviceNew heart allocation policyLeft ventricular assist deviceAllocation system changePost-transplant mortalityOrgan Sharing databaseOutcomes of patientsPost-transplantation outcomesProportion of patientsTime of transplantContinuous-flow LVADPost-transplantation survivalHeart allocation policyNew allocation systemBaseline recipientStatus 1AHeart transplantationIschemic timeLVAD implantationTransplant listImpact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies
Chouairi F, Mullan CW, Sen S, Mori M, Fuery M, Elder RW, Lesse J, Norton K, Clark KA, Miller PE, Mulligan D, Formica R, Rogers JG, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T. Impact of the new heart allocation policy on patients with restrictive, hypertrophic, or congenital cardiomyopathies. PLOS ONE 2021, 16: e0247789. PMID: 33651802, PMCID: PMC7924739, DOI: 10.1371/journal.pone.0247789.Peer-Reviewed Original ResearchConceptsCongenital heart diseaseAllocation system changeHeart allocation systemNew heart allocation policyNew heart allocation systemTransplantation of patientsOrgan Sharing databasePost-transplantation outcomesPost-transplant survivalTime of transplantationMechanical circulatory supportRate of transplantationNumber of patientsHeart allocation policyNew allocation systemStatus 1ACardiac transplantAdult patientsSharing databaseWaitlist survivalCirculatory supportClinical benefitCongenital cardiomyopathyUnited NetworkCHD patientsCurrent status: meeting the regulatory goals of your liver transplant program.
Batra RK, Mulligan DC. Current status: meeting the regulatory goals of your liver transplant program. Current Opinion In Organ Transplantation 2021, 26: 146-151. PMID: 33650996, DOI: 10.1097/mot.0000000000000869.Peer-Reviewed Original ResearchThe demise of islet allotransplantation in the United States: A call for an urgent regulatory update
Witkowski P, Philipson L, Kaufman D, Ratner L, Abouljoud M, Bellin M, Buse J, Kandeel F, Stock P, Mulligan D, Markmann J, Kozlowski T, Andreoni K, Alejandro R, Baidal D, Hardy M, Wickrema A, Mirmira R, Fung J, Becker Y, Josephson M, Bachul P, Pyda J, Charlton M, Millis J, Gaglia J, Stratta R, Fridell J, Niederhaus S, Forbes R, Jayant K, Robertson R, Odorico J, Levy M, Harland R, Abrams P, Olaitan O, Kandaswamy R, Wellen J, Japour A, Desai C, Naziruddin B, Balamurugan A, Barth R, Ricordi C, Collaborative T. The demise of islet allotransplantation in the United States: A call for an urgent regulatory update. American Journal Of Transplantation 2021, 21: 1365-1375. PMID: 33251712, PMCID: PMC8016716, DOI: 10.1111/ajt.16397.Peer-Reviewed Original ResearchConceptsRegulatory frameworkUnited StatesIslet allotransplantationStandard-of-care procedureUS clinical practiceClinical practiceType 1 diabetes mellitusRegulatory distinctionsMinimally manipulated tissuesInvestigation proceduresRegulatory updatesClinical trialsBiological drugsDecades of progressPatientsAllotransplantationIslet transplantationTransplantationIsletsHuman isletsRegulationDrugHuman cellsImminent demiseStateDeep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver
Oestmann PM, Wang CJ, Savic LJ, Hamm CA, Stark S, Schobert I, Gebauer B, Schlachter T, Lin M, Weinreb JC, Batra R, Mulligan D, Zhang X, Duncan JS, Chapiro J. Deep learning–assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver. European Radiology 2021, 31: 4981-4990. PMID: 33409782, PMCID: PMC8222094, DOI: 10.1007/s00330-020-07559-1.Peer-Reviewed Original ResearchConceptsNon-HCC lesionsHepatocellular carcinomaHCC lesionsAtypical imagingGrading systemLI-RADS criteriaAtypical imaging featuresPrimary liver cancerTypical hepatocellular carcinomaAtypical hepatocellular carcinomaContrast-enhanced MRISensitivity/specificityLiver transplantMethodsThis IRBRetrospective studyLiver malignanciesImaging featuresLiver cancerAtypical featuresConclusionThis studyLesionsMRIClinical applicationCarcinomaImage-based diagnosis
2020
Human Small Intestine Transplantation: Segmental Susceptibility to Ischemia Using Different Preservation Solutions and Conditions
Lysyy T, Finotti M, Maina RM, Morotti R, Munoz-Abraham AS, Bertacco A, Ibarra C, Barahona M, Agarwal R, D'Amico F, Rodriguez-Davalos MI, Mulligan D, Geibel J. Human Small Intestine Transplantation: Segmental Susceptibility to Ischemia Using Different Preservation Solutions and Conditions. Transplantation Proceedings 2020, 52: 2934-2940. PMID: 32768284, DOI: 10.1016/j.transproceed.2020.06.031.Peer-Reviewed Original ResearchConceptsContinuous perfusion preservationIntestinal graftIschemic damagePerfusion preservationAppropriate graft selectionCold static storageSmall intestinal graftsSmall intestine graftDifferent preservation solutionsBlinded histological evaluationCross clampIntestine graftsPostoperative complicationsDifferent time pointsIschemic injuryDeceased donorsPatient survivalGraft selectionRinger's lactateHistological evaluationBack tableVascular perfusionLuminal flushAbdominal organsSmall intestineLysis of cold‐storage‐induced microvascular obstructions for ex vivo revitalization of marginal human kidneys
DiRito JR, Hosgood SA, Reschke M, Albert C, Bracaglia LG, Ferdinand JR, Stewart BJ, Edwards CM, Vaish AG, Thiru S, Mulligan DC, Haakinson DJ, Clatworthy MR, Saltzman WM, Pober JS, Nicholson ML, Tietjen GT. Lysis of cold‐storage‐induced microvascular obstructions for ex vivo revitalization of marginal human kidneys. American Journal Of Transplantation 2020, 21: 161-173. PMID: 32627324, PMCID: PMC7775334, DOI: 10.1111/ajt.16148.Peer-Reviewed Original ResearchConceptsNormothermic machine perfusionHuman kidneyMicrovascular obstructionMarginal organsHigh-risk donorsSevere organ shortageLikelihood of complicationsMicrovascular blood flowAccumulation of fibrinogenCold storage injuryTissue plasminogen activatorImmediate translational potentialMicrovascular pluggingRenal functionRenal injuryMachine perfusionTubular epitheliumBlood flowIntravascular releaseOrgan shortagePhysiologic impactKidneyTranslational potentialPlasminogen activatorVivo assessmentClinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020, 72: 287-304. PMID: 32298473, PMCID: PMC7262242, DOI: 10.1002/hep.31281.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusComorbidityConsensusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug InteractionsGastroenterologyHumansImmunosuppression TherapyInternship and ResidencyLiver DiseasesLiver TransplantationOccupational HealthPandemicsPatient SafetyPneumonia, ViralPractice Guidelines as TopicSARS-CoV-2Tissue DonorsConceptsLiver transplant providersTransplant providersLiver diseaseHealthcare providersCOVID-19 pandemicExpert panel consensus statementLiver transplant recipientsCare of patientsCoronavirus disease 2019SARS-CoV-2 virusCOVID-19Transplant recipientsIll patientsLiver patientsClinical recommendationsConsensus statementDisease 2019PatientsPatient careDiseaseCareHepatologistsCOVID-19 pandemic impactBest practice advicePractice adviceFibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation
Tefera J, Revzin M, Chapiro J, Savic L, Mulligan D, Batra R, Taddei T, Jain D, Zhang X. Fibronodular hepatocellular carcinoma—a new variant of liver cancer: clinical, pathological and radiological correlation. Journal Of Clinical Pathology 2020, 74: 31-35. PMID: 32430483, PMCID: PMC7674234, DOI: 10.1136/jclinpath-2020-206574.Peer-Reviewed Original ResearchConceptsAdvanced Barcelona Clinic Liver Cancer stageBarcelona Clinic Liver Cancer stageScirrhous HCCMultiple rounded nodulesNon-peripheral washoutLiver Cancer stageRadiological featuresClinical featuresRadiological correlationCarcinoma variantsCancer stageHCC casesHepatocellular carcinomaLiver cancerFibrotic liverConventional HCCHCCLower ratesHigh rateRounded nodulesProgressionDistinct patternsCarcinomaSpecific variantsLesionsDeceased donors: Defining drug‐related deaths
Cmunt K, Danovitch G, Delmonico F, Fynn‐Thompson F, Glazier A, Grandas J, Gunderson S, Jendrisak M, Johnson HK, Kulkarni S, Lipkowitz G, Meyer K, Mulligan D, Nathan H, Mone T, Moritz M, O'Connor K, Payne W, Souter M, Wood RP. Deceased donors: Defining drug‐related deaths. Clinical Transplantation 2020, 34: e13800. PMID: 32077534, DOI: 10.1111/ctr.13800.Peer-Reviewed Original Research